切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

含抗CD36的 RosetteSep™ CTC富集抗体混合物

免疫密度负选试剂混合物
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #15127_C

免疫密度负选试剂混合物

产品优势

  • 快捷、操作简单
  • 纯度可高达98%
  • 无需分离柱
  • 可与SepMate™联合使用，实现一致的     高通量的样本处理

产品组分包括

  • 含抗CD36的 RosetteSep™ CTC富集抗体混合物     （产品号#15127）
    • 含抗CD36的 RosetteSep™ CTC富集抗体混合物，2mL
  • 含抗CD36的 RosetteSep™ CTC富集抗体混合物     （产品号#15167）
    • 含抗CD36的 RosetteSep™ CTC富集抗体混合物     ，5x2mL
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. Lymphoprep™
    Lymphoprep™

    Density gradient medium for the isolation of mononuclear cells

  2. Dulbecco's Phosphate Buffered Saline with 2% Fetal Bovine Serum
    Dulbecco's Phosphate Buffered Saline with 2% ...

    Cell culture buffer

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

含抗CD36的RosetteSep™ CTC富集抗体混合物用于通过负选从新鲜全血富集循环上皮肿瘤细胞。四聚体抗体复合物可识别CD2、CD16、CD19、CD36、CD38、CD45、D66b以及红细胞（RBC）上的糖蛋白A，从而靶向去除非目的细胞。使用密度梯度离心液如Lymphoprep™（产品号 #18060）离心后     ，非目的细胞会与红细胞一起沉淀。纯化的肿瘤细胞将为血浆和密度梯度离心液的交界界面中高度富集的细胞。    

该抗体混合物适用于小细胞癌样本，包括肺癌样本。若您的样本是乳腺癌样本，请使用含抗CD56的RosetteSep™ CTC富集抗体混合物（产品号 #15137）。

该抗体混合物适用于小细胞癌样本，包括肺癌样本。若您的样本是乳腺癌样本，请使用含抗CD56的RosetteSep™ CTC富集抗体混合物（产品号 #15137）。

该抗体混合物适用于小细胞癌样本，包括肺癌样本。若您的样本是乳腺癌样本，请使用含抗CD56的RosetteSep™ CTC富集抗体混合物（产品号 #15137）。

该抗体混合物适用于小细胞癌样本，包括肺癌样本。若您的样本是乳腺癌样本，请使用含抗CD56的RosetteSep™ CTC富集抗体混合物（产品号 #15137）。

该抗体混合物适用于小细胞癌样本，包括肺癌样本。若您的样本是乳腺癌样本，请使用含抗CD56的RosetteSep™ CTC富集抗体混合物（产品号 #15137）。

磁体兼容性
 
 
亚型
细胞分选试剂盒
 
细胞类型
癌细胞及细胞系
 
种属
人
 
样本来源
Buffy Coat，Whole Blood
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
RosetteSep
 
研究领域
癌症，免疫
 

查看更多 显示更少

实验数据

Typical RosetteSep™ CTC Enrichment Profile

Figure 1. Typical RosetteSep™ CTC Enrichment Profile

In the example above, CAMA (epithelial tumor cell line) cells were seeded into whole blood at a starting frequency of 0.8%. The CAMA cell content of the enriched fraction is 84%. Typically 3.4 to 4.7 log depletion of targeted CD45+ cells is attained.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
RosetteSep™ CTC Enrichment Cocktail Containing Anti-CD36
Catalog #
15127, 15167
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
RosetteSep™ CTC Enrichment Cocktail Containing Anti-CD36
Catalog #
15127, 15167
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (4)

Isolation of Circulating Tumor Cells
Brochure
Isolation of Circulating Tumor Cells
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Isolate Cells from Whole Blood without Columns or Magnets: RosetteSep™ Immunodensity Cell Separation
2:19
Video
Isolate Cells from Whole Blood without Columns or Magnets: RosetteSep™ Immunodensity Cell Separati...
Isolate Highly Purified Cells for HLA Analysis with RosetteSep™ Immunodensity Cell Isolation
1:21
Video
Isolate Highly Purified Cells for HLA Analysis with RosetteSep™ Immunodensity Cell Isolation

常见问题

What is RosetteSep™?

RosetteSep™ is a rapid cell separation procedure for the isolation of purified cells directly from whole blood, without columns or magnets.

How does RosetteSep™ work?

The antibody cocktail crosslinks unwanted cells to red blood cells (RBCs), forming rosettes. The unwanted cells then pellet with the free RBCs when centrifuged over a density centrifugation medium (e.g. Ficoll-Paque™ PLUS, Lymphoprep™).

What factors affect cell recovery?

The temperature of the reagents can affect cell recovery. All reagents should be at room temperature (sample, density centrifugation medium, PBS, centrifuge) before performing the isolations. Layering can also affect recovery so be sure to carefully layer the sample to avoid mixing with the density centrifugation medium as much as possible. Be sure to collect the entire enriched culture without disturbing the RBC pellet. A small amount of density centrifugation medium can be collected without worry.

Which cell samples can RosetteSep™ be used with?

RosetteSep™ can be used with leukapheresis samples, bone marrow or buffy coat, as long as: the concentration of cells does not exceed 5 x 107 per mL (can dilute if necessary); and there are at least 100 RBCs for every nucleated cell (RBCs can be added if necessary).

Can RosetteSep™ be used with previously frozen or cultured cells?

Yes. Cells should be re-suspended at 2 - 5 x 107 cells / mL in PBS + 2% FBS. Fresh whole blood should be added at 250 µL per mL of sample, as a source of red cells.

Can RosetteSep™ be used to enrich progenitors from cord blood?

Yes. Sometimes cord blood contains immature nucleated red cells that have a lower density than mature RBCs. These immature red cells do not pellet over Ficoll™, which can lead to a higher RBC contamination than peripheral blood separations.

Does RosetteSep™ work with mouse cells?

No, but we have developed EasySep™, a magnetic-based cell isolation system which works with mouse and other non-human species.

Which anticoagulant should be used with RosetteSep™?

Peripheral blood should be collected in heparinized Vacutainers. Cord blood should be collected in ACD.

Should the anticoagulant be washed off before using RosetteSep™?

No, the antibody cocktail can be added directly to the sample.

文献 (7)

Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. D. Brungs et al. Scientific reports 2020 jan

Abstract

Circulating tumour cell (CTC) enumeration and profiling has been established as a valuable clinical tool in many solid malignancies. A key challenge in CTC research is the limited number of cells available for study. Ex vivo CTC culture permits expansion of these rare cell populations for detailed characterisation, functional assays including drug sensitivity testing, and investigation of the pathobiology of metastases. We report for the first time the establishment and characterisation of two continuous CTC lines from patients with gastroesophageal cancer. The two cell lines (designated UWG01CTC and UWG02CTC) demonstrated rapid tumorigenic growth in immunodeficient mice and exhibit distinct genotypic and phenotypic profiles which are consistent with the tumours of origin. UWG02CTC exhibits an EpCAM+, cytokeratin+, CD44+ phenotype, while UWG01CTC, which was derived from a patient with metastatic neuroendocrine cancer, displays an EpCAM-, weak cytokeratin phenotype, with strong expression of neuroendocrine markers. Further, the two cell lines show distinct differences in drug and radiation sensitivity which match differential cancer-associated gene expression pathways. This is strong evidence implicating EpCAM negative CTCs in metastasis. These novel, well characterised, long-term CTC cell lines from gastroesophageal cancer will facilitate ongoing research into metastasis and the discovery of therapeutic targets.
View publication
How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. V. Appierto et al. Seminars in cancer biology 2017 APR

Abstract

Breast cancer ranks first among female cancer-related deaths in Western countries. As the primary tumor can often be controlled by surgical resection, the survival of women with breast cancer is closely linked to the incidence of distant metastases. Molecular screening by next generation sequencing highlighted the spatial and temporal heterogeneity of solid tumors as well as the clonal evolution of cancer cells during progression and under treatment pressure. Such findings question whether an optimal assessment of disease progression and a screening for druggable mutations should be based on molecular features of primary or recurrent/metastatic lesions and therefore represent a crucial element for failure or success of personalized medicine. In fact, new targeted therapies may induce only short-term benefit annulled by the emergence of resistant clones with new driver mutations which would need to be rapidly and reliably identified. Serial tissue sampling is therefore essential but, unfortunately, also represents a problem since biopsies from solid lesions, which are invasive and potentially painful and risky, cannot be easily repeatedly sampled, are inaccessible or may not fully reflect tumor heterogeneity. The need to early detect and strike this moving target" is now directing the scientific community towards liquid biopsy-based biomarkers which include circulating tumor cells (CTC) and cell-free circulating tumor DNA (ctDNA) can be repeatedly assessed through non-invasive and easy-to-perform procedures and may act as reliable read-outs of functional and molecular features of recurrent/metastatic lesions. In this review we summarize the outcome of CTCs and ctDNA in breast cancer with special reference on their role on unveiling and overcoming tumor heterogeneity on their potential relevance for tumor surveillance and monitoring and for the selection of therapeutic options. Finally we propose integration between blood-based molecular and clinical approaches for monitoring disease progression according to the specific pattern of recurrence of the most aggressive breast cancer molecular subtypes."
View publication
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. A. Kuske et al. Scientific reports 2016 DEC

Abstract

The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could address this. This study aimed to improve CTC detection in non-metastatic PCa patients by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT. Peripheral blood samples from high-risk PCa patients were screened for CTCs before and three months after radical prostatectomy (RP). Combining the results of both time points, CTCs were detected in 37{\%}, 54.9{\%} and 58.7{\%} of patients using CellSearch, CellCollector and EPISPOT, respectively. The cumulative positivity rate of the three CTC assays was 81.3{\%} (87/107) with 21.5{\%} (23/107) of patients harboring ≥5 CTCs/7.5 ml blood. Matched pair analysis of 30 blood samples taken before and after surgery indicated a significant decrease in CTCs captured by the CellCollector from 66{\%} before RP to 34{\%} after therapy (p = 0.031). CTC detection by EPISPOT before RP significantly correlated with PSA serum values (p {\textless} 0.0001) and clinical tumor stage (p = 0.04), while the other assays showed no significant correlations. In conclusion, CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer.
View publication
View All Publications

更多信息

更多信息
种属 Human
Magnet Compatibility  
样本来源 Buffy Coat, Whole Blood
Selection Method Negative
质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.